News ArticleEmcure Pharmaceuticals Posts INR 28,204.71 Million Revenue for Q2 Ending September 2026
Unaudited consolidated results for half-year ended September 30, 2026, approved and reviewed by statutory auditors B S R & Co. LLP
Emcure Pharmaceuticals Limited announced its unaudited consolidated financial results for the quarter and half-year ended September 30, 2026. The company reported total revenue from operations of INR 28,204.71 million for Q2 and INR 54,009.18 million for H1 FY2026, with detailed financial statements reviewed by B S R & Co. LLP and the performance covering multiple international subsidiaries.
Emcure Pharmaceuticals Limited
Financial Results
Emcure Pharmaceuticals Limited disclosed its unaudited consolidated financial results for the quarter and half-year ended September 30, 2026, highlighting total revenues from operations of INR 28,204.71 million in Q2 and INR 54,009.18 million for the half-year period.
The board meeting held on November 3, 2026, resulted in the approval of the company's unaudited standalone and consolidated financial statements reviewed by the Audit Committee and statutory auditors B S R & Co. LLP.
The consolidated results include financials from 26 subsidiaries across various countries including India, UK, Nigeria, South Africa, Brazil, Mexico, Chile, and others.
Total income for the quarter ended September 30, 2026, stood at INR 28,237.25 million, combining revenue from operations and other income.
The period also covered the half-year ended September 30, 2026, with total income reported at INR 54,062.43 million, compared to INR 43,771.78 million in the same period last year.
Highlights
- Total revenue from operations was INR 28,204.71 million for Q2 2026 and INR 54,009.18 million for H1 2026.
- The unaudited results were reviewed and recommended by the Audit Committee and approved by the board on November 3, 2026.
- Statutory auditors B S R & Co. LLP issued unmodified limited review reports on the financial results.
- The consolidated results include 26 subsidiaries globally, adding significant contributions to the group's financials.
- Other income for Q2 2026 was INR 32.54 million, contributing to a total income of INR 28,237.25 million for the quarter.
Key Data Snapshot
What happened
- Emcure Pharmaceuticals Limited approved unaudited standalone and consolidated financial results for Q2 and H1 ended September 30, 2026.
- The results were reviewed by the Audit Committee and statutory auditors B S R & Co. LLP.
- The consolidated results include the financials of 26 subsidiaries across various countries.
Key details
- Q2 revenue from operations reached INR 28,204.71 million, and total income was INR 28,237.25 million including other income.
- For H1 ended September 30, 2026, revenue was INR 54,009.18 million, and total income was INR 54,062.43 million.
- The audited results are prepared in compliance with Indian Accounting Standard 34 (Ind AS 34) and SEBI Listing Regulations.
- Limited review reports issued by B S R & Co. LLP did not identify any material misstatements in the financials.
Regulatory and governance context
- The announcement complies with SEBI Listing Obligations and Disclosure Requirements Regulations 2015, including timely board meeting and disclosure rules.
- Limited review conducted as per Standard on Review Engagements 2410 and SEBI circulars.
- Results cover interim financials as per recognized Indian accounting standards.
Highlights
- Total revenue from operations was INR 28,204.71 million for Q2 2026 and INR 54,009.18 million for H1 2026.
- The unaudited results were reviewed and recommended by the Audit Committee and approved by the board on November 3, 2026.
- Statutory auditors B S R & Co. LLP issued unmodified limited review reports on the financial results.
- The consolidated results include 26 subsidiaries globally, adding significant contributions to the group's financials.
- Other income for Q2 2026 was INR 32.54 million, contributing to a total income of INR 28,237.25 million for the quarter.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- Indian Accounting Standard 34 ('Interim Financial Reporting')
- SEBI Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026
Source Information
More News on Financial Results
View allLatest corporate announcements and market updates in Financial Results.
Gujarat Fluorochemicals Posts Rs 689 Crore Profit Before Tax in Q2 and H1 FY2026-27 on Rs 3,002 Crore Revenue
Gujarat Fluorochemicals Limited has announced unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026, recording a profit before tax of Rs 689 crore for the half-year period and total revenue from operations of Rs 3,002 crore in the quarter.
Read Full Story
Solar Industries India Announces Q2 & H1 2026 Unaudited Financial Results and Names Price Waterhouse as Joint Statutory Auditor
Solar Industries India Limited has released its unaudited standalone and consolidated financial results for the quarter and half year ending September 30, 2026, alongside appointing M/s Price Waterhouse Chartered Accountants LLP as joint statutory auditors starting from the 2027 AGM.
Read Full Story
State Bank of India Reports ₹44,159.17 Crore Net Profit Before Share for Half Year Ended September 30, 2026
State Bank of India (SBI) disclosed its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, reporting a net profit before share in the profit of associates and minority interest of ₹44,159.17 crore for the half year.
Read Full Story
